The Medtech Industry To Give Impetus To The Urothelial Carcinoma Diagnostics Market

The Urothelial Carcinoma Diagnostics Market is meant to grow on a splendid note in the next decade. With technology creeping in, the time-consuming routine is being taken over by telehealth/e-Health records. Almost everything that was happening in person has been taken over by remote monitoring. This has helped in transcending the geographical barriers as well. These would be the trends concerning the Urothelial Carcinoma Diagnostics Market in the future.

According to World Health Organization (WHO) estimates, every year, 3.8 Mn new cases of urothelial carcinoma occur around the world, with the recurrence rate being nearly 30-50%. However, early detection by use of modern diagnostics enables quick medical decision-making and consequent treatment for urothelial carcinoma. Accuracy in urothelial carcinoma diagnostics plays a significant role in the reduction of treatment costs.

Moreover, increased demand for treatment of urothelial carcinoma is a key driver for increasing revenue inflow from diagnostic tests and procedures. However, development of effective urothelial carcinoma screening methods will play a significant role in the early detection and subsequent reduction in mortality rates. Furthermore, technological advancements in diagnostic methods such as the adoption of diagnostic imaging procedures, rapid molecular diagnostic kits, and use of biomarker testing in urothelial carcinoma screening programs are some other factors that will aid the growth of the urothelial carcinoma diagnostics market.

How About Looking Through The Sample Of Urothelial Carcinoma Diagnostics Market Report? https://www.persistencemarketresearch.co/samples/14128

Companies covered in Urothelial Carcinoma Diagnostics Market Report

GE Healthcare
Roche Holding
Illumina
IDL Biotech
Agilent Technologies
Olympus Corporation
Philips Healthcare
Abbott Molecular
Bio-Rad Laboratories, Inc
Thermo Fisher Scientific, Inc.( Qiagen N.V.)
Danaher Corporation (Cepheid)
How About Step-By-Step Insights To Urothelial Carcinoma Diagnostics Market? Look Through The "Methodology" Employed! https://www.persistencemarketresearch.co/methodology/14128

According to the latest report published by PMR, the global urothelial carcinoma diagnostics market was valued at US$ 1 Bn in 2020, and is expected to progress at a CAGR of over 11% during the forecast period (2020-2030).

Key Takeaways from Urothelial Carcinoma Diagnostics Market Study

The reagent and kits segment, under product type, is expected to contribute more than 70% of revenue share in the urothelial carcinoma diagnostics market.
By test type, molecular diagnostic tests accounted for the highest revenue in 2019. Rapid and sensitive detection is anticipated to drive demand for urothelial carcinoma diagnostics.
Based on end user, the hospitals segment accounts for a major revenue share in the urothelial carcinoma diagnostics market.
Leading players launching rapid diagnostic products with advances technology are expected to dominate the urothelial carcinoma diagnostics market space.
Governments of various countries are organizing cancer screening programs and are spreading awareness, which is creating significant demand for urothelial carcinoma diagnostics.
The COVID-19 outbreak has resulted in manufacturing disruptions and also decreased demand, which is projected to impede market growth in the near term.
Want To Keep A Tab On The Latest Findings In The Urothelial Carcinoma Diagnostics Market? Purchase Our Urothelial Carcinoma Diagnostics Market Report Now! https://www.persistencemarketresearch.com/checkout/14128

"Rise in prevalence of urothelial carcinoma and demand for early detection for preventive treatments will boost the global urothelial carcinoma diagnostics market," says a PMR analyst.

Acquisitions and Partnerships - Key Strategies amongst Market Players

Key players in the urothelial carcinoma diagnostics market are looking forward to strengthening their product portfolios through the launch of new products. For instance, in 2017, Roche received FDA approval for the complementary PD-L1 (SP263) biomarker test in urothelial carcinoma. In August, 2018, Agilent Technologies, Inc announced that the US Food and Drug Administration approved its Dako PD-L1 IHC 22C3 pharmDx assay for expanded use as a companion diagnostic test for Merck's anti-PD1 immunotherapy Keytruda (pembrolizumab) for urothelial carcinoma.

Various players in the urothelial carcinoma diagnostics market are focusing on growth strategies such as acquisitions and partnerships. For example, in 2020, Thermo Fisher Scientific signed an agreement with Janssen to co-develop companion diagnostics for cancer.

What Does the Report Cover?

Persistence Market Research offers a unique perspective and actionable insights on the urothelial carcinoma diagnostics market in its latest study, presenting historical demand assessment of 2015-2019 and projections for 2020-2020, on the basis of product type (reagents and kits, instruments), test type (urinalysis test, molecular diagnostic test, biomarker test, imaging test, cytoscopy, ureteroscopy), and end user (hospitals, diagnostic laboratories, research and academic institutes, clinical research organizations), across seven key regions.

Persistence Market Research
Address - 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. - +1-646-568-7751
USA-Canada Toll-free - +1 800-961-0353
Sales - sales@persistencemarketresearch.com

Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers' experience by acting as the "missing" link between "customer relationships" and "business outcomes'. The best possible returns are assured therein.

This release was published on openPR.